BridgeBio Oncology Therapeutics Inc. Common Stock (BBOT)

About BBOT

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

88

Website

bbotx.com/

Fundamentals

1-day range

$8.69$9.16

Market cap

$660.88M

P/E (trailing)

—

P/E (forward)

-3.62

EPS (trailing)

$-2.30

Dividend yield

—

Beta

0.41

Avg. volume

373.2K

Forecasts

10 analyst ratings

BridgeBio Oncology Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BBOT

  BridgeBio Oncology Therapeutics Inc. Common Stock

  $8.74

  ▼ 4.79%
  Market cap $660.88MP/E —
  $7$14.87
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $676.28MP/E —
  $1.54$18.33
• OCS

  Oculis Holding AG Ordinary shares

  $12.21

  ▼ 1.77%
  Market cap $689.43MP/E —
  $10.52$34.48
• CTMX

  CytomX Therapeutics Inc. Common Stock

  $3.22

  ▼ 5.99%
  Market cap $690.12MP/E —
  $1.9$8.21
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $723.93MP/E —
  $53.99$170
• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $592.31MP/E 3.53
  $6.13$14.96
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.77$124.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
  benzinga · 8/14/2026
• JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
  Benzinga · 8/14/2026
• BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/11/2026
• BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
  Yahoo · 8/11/2026
• BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
  Benzinga · 8/11/2026

• Elmelech Idan · July 1, 2026 · Tax Withholding

  343 @ $7.8
• Yong Ben · July 1, 2026 · Tax Withholding

  1.0K @ $7.8
• Beltran Pedro · July 1, 2026 · Tax Withholding

  1.0K @ $7.8
• Cobo Marc · July 1, 2026 · Tax Withholding

  125 @ $7.8
• Bihua Chen · July 1, 2026 · J

  130.9K
• Bihua Chen · July 1, 2026 · J

  1.70M
• Bihua Chen · July 1, 2026 · J

  2.69M
• Bihua Chen · July 1, 2026 · J

  4.53M
• Jake Bauer · June 16, 2026 · Grant

  31.7K
• Bihua Chen · June 16, 2026 · Grant

  31.7K
• Frank McCormick · June 16, 2026 · Grant

  31.7K
• Elmelech Idan · May 10, 2026 · Grant

  758.2K
• Beltran Pedro · May 10, 2026 · Grant

  1.10M
• Yong Ben · April 1, 2026 · Tax Withholding

  1.0K @ $9.03
• Beltran Pedro · April 1, 2026 · Tax Withholding

  1.0K @ $9.03

Institutional Ownership

March 31, 2026

Total shares held

57.11M

Total value held

$506.79M

Institutional holders

64